BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32856506)

  • 1. Let-7b regulates the adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells.
    Zhou X; Ma X; Sun H; Li X; Cao H; Jiang Y; Wang P; Xie S; Li Y; Sun Y
    Leuk Lymphoma; 2020 Dec; 61(14):3451-3459. PubMed ID: 32856506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
    Ma X; Zhou X; Qu H; Ma Y; Yue Z; Shang W; Wang P; Xie S; Li Y; Sun Y
    Oncol Rep; 2018 Apr; 39(4):1910-1918. PubMed ID: 29436678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germacrone reverses adriamycin resistance in human chronic myelogenous leukemia K562/ADM cells by suppressing MDR1 gene/P-glycoprotein expression.
    Pan J; Miao D; Chen L
    Chem Biol Interact; 2018 May; 288():32-37. PubMed ID: 29655913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
    Zhao L; Shan Y; Liu B; Li Y; Jia L
    Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Let-7b attenuates cisplatin resistance and tumor growth in gastric cancer by targeting AURKB.
    Han X; Zhang JJ; Han ZQ; Zhang HB; Wang ZA
    Cancer Gene Ther; 2018 Dec; 25(11-12):300-308. PubMed ID: 30237418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
    Marsola APZC; Simões BP; Palma LC; Berzoti-Coelho MG; Burin SM; de Castro FA
    Med Oncol; 2018 Jan; 35(3):26. PubMed ID: 29387948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.
    Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y
    Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting glycometabolic reprogramming to restore the sensitivity of leukemia drug-resistant K562/ADM cells to adriamycin.
    Zhang X; Chen J; Ai Z; Zhang Z; Lin L; Wei H
    Life Sci; 2018 Dec; 215():1-10. PubMed ID: 30473023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemia.
    Lu Z; Xu N; He B; Pan C; Lan Y; Zhou H; Liu X
    J Exp Clin Cancer Res; 2017 Mar; 36(1):43. PubMed ID: 28283035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
    Li X; Pang J; Xue W; Wang Y; Tian T; Elgehama A; Wu X; Wu X; Sun Y; Qiu H; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2018 Dec; 360():249-256. PubMed ID: 30290167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1.
    Li Y; Zhao L; Li N; Miao Y; Zhou H; Jia L
    Oncol Rep; 2017 Apr; 37(4):2193-2200. PubMed ID: 28260112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells.
    Chen JR; Jia XH; Wang H; Yi YJ; Li YJ
    Oncol Rep; 2017 May; 37(5):2735-2742. PubMed ID: 28358418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
    Cai H; Li L; Jiang J; Zhao C; Yang C
    Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down-regulated let-7b-5p represses glycolysis metabolism by targeting AURKB in asthenozoospermia.
    Zhou R; Zhang Y; Du G; Han L; Zheng S; Liang J; Huang X; Qin Y; Wu W; Chen M; Wu D; Song L; Fu G; Lv S; Xia Y; Lu C; Wang X
    Gene; 2018 Jul; 663():83-87. PubMed ID: 29653228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.